KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Pediatrics / 2020 / Cilt: 62 - Sayı: 6

Clitoromegaly caused by ovarian stimulation in a preterm newborn: ovarian hyperstimulation syndrome of preterm babies

Elvan BAYRAMOĞLU
Şenay ERDEVE SAVAŞ
Semra ÇETİNKAYA
Zehra AYCAN
Betül Emine DERİNKUYU
İstemi Han ÇELİK
Sayfa
1088–1093
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

This is the first case of POHS developing pericardial effusion.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Preterm ovarian hyperstimulation syndrome (POHS) is an uncommon disorder characterized by prematurity, hypogastric and upper leg swelling, high serum estradiol and gonadotropin levels, and ovarian cysts.
📊
Temel Bulgular & Veri:A preterm baby who was born at 24 gestational weeks was referred to our clinic for ambiguous genitalia on day 118 of life.
💡
Sonuç & Katkı:This is the first case of POHS developing pericardial effusion.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Background. Preterm ovarian hyperstimulation syndrome (POHS) is an uncommon disorder characterized by prematurity, hypogastric and upper leg swelling, high serum estradiol and gonadotropin levels, and ovarian cysts. Immaturity of the gonadal axis is accepted as the cause. But still, other etiological factors are suspected.Case. A preterm baby who was born at 24 gestational weeks was referred to our clinic for ambiguous genitalia on day 118 of life. Labia majora and clitoris was edematous. Clitoris length was 1.5 cm. On laboratory evaluation: 17OH-Progesterone: 1.84 ng/ml, dehydroepiandrosterone sulphate (DHEA-S): 139 µg/dl, total testosterone (T.T): 88 ng/dl, luteinizing hormone (LH): 22.5 mIU/l, Follicle stimulating hormone (FSH): 15.7 mIU/l, estradiol (E2): 447 pg/ml. Karyotype analysis was 46, XX. There was a 25x14x12 mm ovarian cyst detected on ultrasound. On follow-up, E2 levels and cyst size increased, and there was 4 mm pericardial effusion on echocardiography at the time. Conclusion. In this paper, we present a case with POHS and to discuss possible pathophysiological mechanisms and treatment. This is the first case of POHS developing pericardial effusion.

🔖

Bu Makaleye Atıf Yap

BAYRAMOĞLU, E., SAVAŞ, Ş. E., ÇETİNKAYA, S., AYCAN, Z., DERİNKUYU, B. E., ÇELİK, İ. H. (2020). Clitoromegaly caused by ovarian stimulation in a preterm newborn: ovarian hyperstimulation syndrome of preterm babies. Turkish Journal of Pediatrics, Cilt: 62 - Sayı: 6, 1088–1093. https://ajindex.com/articles/411971

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Starzyk J, Wójcik M, Wojtyś J, Tomasik P, Mitkowska Z, Pietrzyk JJ. Ovarian hyperstimulation syndrome in newborns--a case presentation and literature review. Horm Res 2009; 71: 60-64
  2. Mondal R, Chatterjee K, Samanta M, et al. Clitoral length and anogenital ratio in Indian newborn girls. Indian Pediatr 2016; 53: 299-303
  3. Forest MG, De Peretti E, Bertrand J. Hypothalamicpituitary-gonadal relationships in man from birth to puberty. Clin Endocrinol (Oxf) 1976; 5: 551-569
  4. Acherman JC. Endocrinology of newborn. In: Brook CGD, Clayton P, Brown R (eds). Brook’s Clinical Pediatric Endocrinology (5th ed). Development of the Reproductive Systems (Chapter 8). Oxford: Blackwell, 2005; 153-170
  5. Greaves RF, Hunt RW, Chiriano AS, Zacharin MR. Luteinizing hormone and follicle-stimulating hormone levels in extreme prematurity: development of reference intervals. Pediatrics 2008; 121: e574-e580
  6. Halis H, Memur S, Korkmaz L, Baştuğ O, Güneş T, Kurtoğlu S. Ovarian hyperstimulation syndrome treated by medroxyprogesterone acetate. J Pediatr Endocrinol Metab 2014; 27: 997-999
  7. Elchalal U, Schenker JG. The pathophysiology of ovarian hyperstimulation syndrome--views and ideas. Hum Reprod 1997; 12: 1129-1137
  8. Irani M, Robles A, Gunnala V, Chung P, Rosenwaks Z. Unilateral pleural effusion as the sole clinical presentation of severe ovarian hyperstimulation syndrome: a systematic review. Gynecol Endocrinol 2018; 34: 92-99
  9. Delvigne A, Demoulin A, Smitz J, et al. The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. I. Clinical and biological features. Hum Reprod 1993; 8: 1353-1360
  10. Delbaere A, Bergmann PJ, Gervy-Decoster C, Camus M, de Maertelaer V, Englert Y. Prorenin and active renin concentrations in plasma and ascites during severe ovarian hyperstimulation syndrome. Hum Reprod 1997; 12: 236-240
  11. McClure N, Healy DL, Rogers PA, et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 1994; 344: 235-236
  12. Loret de Mola JR, Arredondo-Soberon F, Randle CP, Tureck RT, Friedlander MA. Markedly elevated cytokines in pleural effusion during the ovarian hyperstimulation syndrome: transudate or ascites? Fertil Steril 1997; 67: 780-782
  13. Balasch J, Reverter JC, Fabregues F, Tassies D, Ordinas A, Vanrell JA. Increased induced monocyte tissue factor expression by plasma from patients with severe ovarian hyperstimulation syndrome. Fertil Steril 1996;